Company Description
Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases.
The company’s lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425.
It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease; and a series of bispecific antibodies targeting DR3 and other clinically validated targets.
In addition, the company is involved in the advancement of its lead TRIM7 inhibitors through preclinical development as future internal pipeline candidates in oncology.
Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
| Country | United States |
| Founded | 2016 |
| IPO Date | Oct 9, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 44 |
| CEO | Taylor Schreiber |
Contact Details
Address: 500 West 5th Street, Suite 1200 Austin, Texas 78701 United States | |
| Phone | 512 900 4690 |
| Website | shattucklabs.com |
Stock Details
| Ticker Symbol | STTK |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001680367 |
| CUSIP Number | 82024L103 |
| ISIN Number | US82024L1035 |
| Employer ID | 81-2575858 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Taylor H. Schreiber M.D., Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Andrew R. Neill M.B.A. | Chief Financial Officer |
| Dr. Arunthathy Nirmalini Pandite M.B.A., M.D. | Chief Medical Officer |
| Dr. Abhinav A. Shukla Ph.D. | Chief Technical Officer |
| Conor Richardson CPA | Vice President of Investor Relations |
| Dr. Stephen Stout J.D., Ph.D. | General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer |
| Casi DeYoung | Chief Business Officer |
| Dr. Thomas Lampkin Pharm.D. | Senior Vice President of Regulatory Affairs |
| George Fromm Ph.D. | Co-Chief Scientific Officer |
| Suresh de Silva Ph.D. | Co-Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 6, 2025 | SCHEDULE 13D/A | Filing |
| Aug 5, 2025 | 8-K | Current Report |
| Jul 29, 2025 | SCHEDULE 13G/A | Filing |
| Jul 16, 2025 | SCHEDULE 13G/A | Filing |
| Jul 15, 2025 | 8-K | Current Report |
| May 21, 2025 | ARS | Filing |
| May 21, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 21, 2025 | DEF 14A | Other definitive proxy statements |
| May 1, 2025 | 10-Q | Quarterly Report |
| May 1, 2025 | 8-K | Current Report |